NCT01545817 - Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 19, 2012

Primary Completion Date

November 18, 2016

Study Completion Date

November 18, 2016

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Pazopanib followed by everolimus

All patients received Pazopanib (800 mg once daily orally continuous dosing) until disease progression then second line everolimus (10 mg once daily orally continuous dosing)

Trial Locations (15)

2217

Novartis Investigative Site, Kogarah

2606

Novartis Investigative Site, Garran

3011

Novartis Investigative Site, Footscay

3199

Novartis Investigative Site, Frankston

4066

Novartis Investigative Site, Auchenflower

4215

Novartis Investigative Site, Southport

5011

Novartis Investigative Site, Woodville

5037

Novartis Investigative Site, Kurralta Park

5112

Novartis Investigative Site, Elizabeth Vale

6001

Novartis Investigative Site, Perth

6009

Novartis Investigative Site, Nedlands

10408

Novartis Investigative Site, Gyeonggi-do

03080

Novartis Investigative Site, Seoul

135-710

Novartis Investigative Site, Seoul

138-736

Novartis Investigative Site, Seoul